help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Suzuki, T.
Right arrow Articles by Sasano, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Suzuki, T.
Right arrow Articles by Sasano, H.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Breast Cancer
The Journal of Clinical Endocrinology & Metabolism Vol. 86, No. 5 2250-2257
Copyright © 2001 by The Endocrine Society

Original Studies

5{alpha}-Reductases in Human Breast Carcinoma: Possible Modulator of in Situ Androgenic Actions1

Takashi Suzuki, Andrew D. Darnel, Jun-Ichi Akahira, Naohiro Ariga, Sayaka Ogawa, Chika Kaneko, Junji Takeyama, Takuya Moriya and Hironobu Sasano

Department of Pathology, Tohoku University School of Medicine (T.S., A.D.D., J.-I.A., S.O., C.K., J.T., H.S.), and Department of Pathology, Tohoku University Hospital (N.A., T.M.), Sendai 980-8575, Japan

Address all correspondence and requests for reprints to: Takashi Suzuki, M.D., Department of Pathology, Tohoku University School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai, 980-8575, Japan. E-mail: t-suzuki{at}patholo2.med.tohoku.ac.jp

The expression of 5{alpha}-reductase types 1 and 2 was examined in human breast carcinoma using immunohistochemistry and RT-PCR. Immunoreactivity for 5{alpha}-reductase isozymes was also correlated with various clinicopathological parameters to examine possible local regulatory mechanisms of sex steroids, including progesterone and androgens, in human breast carcinoma tissues. Immunoreactivity for 5{alpha}-reductase type 1 was detected in the cytoplasm and possibly in the nuclear membrane of tumor cells in 35 of 60 invasive ductal carcinomas (58%), and type 2 signal was detected in 9 of these 60 cases (15%). The results from RT-PCR (n = 8) were consistent with those from immunohistochemistry. A significant positive correlation was detected between 5{alpha}-reductase type 1 immunoreactivity and androgen and progesterone receptor A or B labeling indexes, and immunoreactivities of 5{alpha}-reductase type 2, 17ß-hydroxysteroid dehydrogenase type 5, or 3ß-hydroxysteroid dehydrogenase, which recognizes both types I and II. An inverse correlation was detected between 5{alpha}-reductase type 1 immunoreactivity and tumor size, histological grade, or Ki-67 labeling index. 5{alpha}-Reductase type 2 immunoreactivity was significantly correlated with 17ß-hydroxysteroid dehydrogenase type 5 immunoreactivity, but not with other parameters. This study suggests that 5{alpha}-reductase type 1 is mainly expressed in human breast carcinoma, which may play an important role in the in situ production and actions of the potent androgen, 5{alpha}-dihydrotestosterone, including inhibition of cancer cell proliferation, in hormone-dependent human breast carcinoma.




This article has been cited by other articles:


Home page
 Endocr Relat CancerHome page
R. Shibuya, T. Suzuki, Y. Miki, K. Yoshida, T. Moriya, K. Ono, J.-i. Akahira, T. Ishida, H. Hirakawa, D. B Evans, et al.
Intratumoral concentration of sex steroids and expression of sex steroid-producing enzymes in ductal carcinoma in situ of human breast
Endocr. Relat. Cancer, March 1, 2008; 15(1): 113 - 124.
[Abstract] [Full Text] [PDF]

Home page
 J EndocrinolHome page
J. Enriquez, A. E. Lemus, J. Chimal-Monroy, H. Arzate, G. A Garcia, B. Herrero, F. Larrea, and G. Perez-Palacios
The effects of synthetic 19-norprogestins on osteoblastic cell function are mediated by their non-phenolic reduced metabolites
J. Endocrinol., June 1, 2007; 193(3): 493 - 504.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y. Miki, T. Suzuki, C. Tazawa, Y. Yamaguchi, K. Kitada, S. Honma, T. Moriya, H. Hirakawa, D. B. Evans, S.-i. Hayashi, et al.
Aromatase Localization in Human Breast Cancer Tissues: Possible Interactions between Intratumoral Stromal and Parenchymal Cells
Cancer Res., April 15, 2007; 67(8): 3945 - 3954.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
J. P Wiebe
Progesterone metabolites in breast cancer.
Endocr. Relat. Cancer, September 1, 2006; 13(3): 717 - 738.
[Abstract] [Full Text] [PDF]

Home page
 J EndocrinolHome page
G. Perez-Palacios, R. Santillan, R. Garcia-Becerra, E. Borja-Cacho, F. Larrea, P. Damian-Matsumura, L. Gonzalez, and A. E Lemus
Enhanced formation of non-phenolic androgen metabolites with intrinsic oestrogen-like gene transactivation potency in human breast cancer cells: a distinctive metabolic pattern.
J. Endocrinol., September 1, 2006; 190(3): 805 - 818.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. F. Macedo, Z. Guo, S. L. Tilghman, G. J. Sabnis, Y. Qiu, and A. Brodie
Role of androgens on mcf-7 breast cancer cell growth and on the inhibitory effect of letrozole.
Cancer Res., August 1, 2006; 66(15): 7775 - 7782.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
T. Suzuki, Y. Miki, Y. Nakamura, T. Moriya, K. Ito, N. Ohuchi, and H. Sasano
Sex steroid-producing enzymes in human breast cancer
Endocr. Relat. Cancer, December 1, 2005; 12(4): 701 - 720.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
Y. Nakamura, T. Suzuki, M. Nakabayashi, M. Endoh, K. Sakamoto, Y. Mikami, T. Moriya, A. Ito, S. Takahashi, S. Yamada, et al.
In situ androgen producing enzymes in human prostate cancer
Endocr. Relat. Cancer, March 1, 2005; 12(1): 101 - 107.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. Utsunomiya, K. Ito, T. Suzuki, T. Kitamura, C. Kaneko, T. Nakata, H. Niikura, K. Okamura, N. Yaegashi, and H. Sasano
Steroid Sulfatase and Estrogen Sulfotransferase in Human Endometrial Carcinoma
Clin. Cancer Res., September 1, 2004; 10(17): 5850 - 5856.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. Frasor, F. Stossi, J. M. Danes, B. Komm, C. R. Lyttle, and B. S. Katzenellenbogen
Selective Estrogen Receptor Modulators: Discrimination of Agonistic versus Antagonistic Activities by Gene Expression Profiling in Breast Cancer Cells
Cancer Res., February 15, 2004; 64(4): 1522 - 1533.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
C. H. van Gils, N. C. Onland-Moret, M. Roest, P. A. H. van Noord, and P. H. M. Peeters
The V89L Polymorphism in the 5-{alpha}-Reductase Type 2 Gene and Risk of Breast Cancer
Cancer Epidemiol. Biomarkers Prev., November 1, 2003; 12(11): 1194 - 1199.
[Abstract] [Full Text]

Home page
 Mol. Endocrinol.Home page
J.-L. Carsol, S. Gingras, and J. Simard
Synergistic Action of Prolactin (PRL) and Androgen on PRL-Inducible Protein Gene Expression in Human Breast Cancer Cells: A Unique Model for Functional Cooperation between Signal Transducer and Activator of Transcription-5 and Androgen Receptor
Mol. Endocrinol., July 1, 2002; 16(7): 1696 - 1710.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2001 by The Endocrine Society